Skip to content
You are now leaving to visit

Akcea and Ionis Announce Upcoming Data Presentations at the 2019 American College of Cardiology Meeting (ACC.19)

Presentations focus on the benefits of treatment with TEGSEDI™ (inotersen) and results show continued efficacy with long-term exposure in the NEURO-TTR open-label extension study BOSTON and CARLSBAD, Calif., March 15, 2019 (GLOBE NEWSWIRE) — Akcea Therapeutics, Inc.